TY - JOUR 
A1 - Barbazán García, Jorge
AU - Muinelo Romay , Laura
AU - Vieito Villar, María
AU - Candamio Folgar, Sonia
AU - Díaz-López, A.
AU - Cano, A.
AU - Gómez-Tato, A.
AU - Casares de Cal, M.e L
AU - Abal, M.
AU - López López, Rafael
T1 - A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer
Y1 - 2014
SN - 0020-7136
UR - http://hdl.handle.net/20.500.11940/4499
AB - Circulating tumor cells (CTCs), proposed as major players in cancer dissemination, have demonstrated clinical prognostic significance in several cancer types. However, their predictive value remains unclear. Here we evaluated the clinical utility of six CTC markers (tissue specific and epithelial to mesenchymal transition transcripts) both as prognostic and predictive tools in metastatic colorectal cancer (mCRC) patients. CTCs were immunoisolated from blood in 50 mCRC patients at baseline and at 4 and 16 weeks after treatment onset. Expression levels of GAPDH, VIL1, CLU, TIMP1, LOXL3 and ZEB2 were determined by qualitative polymerase chain reaction and normalized to the unspecific cell isolation marker CD45. At baseline, median progression-free survival (PFS) and overall survival (OS) for patients with high CTC markers were 6.3 and 12.7 months, respectively, versus 12.7 and 24.2 for patients with low CTC markers (PFS; p = 0.0003; OS; p = 0.044). Concerning response to therapy, PFS and OS for patients with increased CTC markers along treatment were, respectively, 6.6 and 13.1 months, compared with 12.7 and 24.3 for patients presenting CTC markers reduction (PFS; p = 0.004; OS; p = 0.007). Of note, CTC markers identified therapy-refractory patients not detected by standard image techniques. Patients with increased CTC markers along treatment, but classified as responders by computed tomography, showed significantly shorter survival times (PFS: 7.8 vs. 13.2; OS: 14.4 vs. 24.4; months). In conclusion, we have generated a CTC marker panel for prognosis evaluation and the identification of patients benefiting or not from therapy in mCRC. Our methodology efficiently classified patients earlier than routine computed tomography and from a minimally invasive liquid biopsy.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Antibodies, Monoclonal, Humanized
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Bevacizumab
KW - Biomarkers, Tumors
KW - Camptothecin
KW - Capecitabine
KW - Cetuximab
KW - Colorectal Neoplasms
KW - Deoxycytidine
KW - Epithelial-Mesenchymal Transition
KW - Female
KW - Fluorouracil
KW - Follow-Up Studies
KW - Humans
KW - Irinotecan
KW - Liver Neoplasms
KW - Male
KW - Middle Aged
KW - Neoplasm Staging
KW - Neoplastic Cells, Circulating
KW - Organoplatinum Compounds
KW - Oxaliplatin
KW - Prognosis
KW - Survival Rate
LA - eng
ER -